Predicting long‐term clinical stability in amyloid‐positive subjects by FDG‐PET
Abstract Imaging biomarkers can be used to screen participants for Alzheimer's disease clinical trials. To test the predictive values in clinical progression of neuropathology change (amyloid‐PET) or brain metabolism as neurodegeneration biomarker ([18F]FDG‐PET), we evaluated data from N = 268...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2019-06-01
|
| Series: | Annals of Clinical and Translational Neurology |
| Online Access: | https://doi.org/10.1002/acn3.782 |